Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Guggenheim Analyst Says

Maze Therapeutics (NASDAQ:MAZE) had its price objective increased by equities research analysts at Guggenheim from $46.00 to $58.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 28.04% from the stock’s current price.

MAZE has been the topic of a number of other research reports. Wedbush lifted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Wells Fargo & Company began coverage on Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. BTIG Research boosted their price target on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, January 16th. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $48.57.

Maze Therapeutics Stock Performance

MAZE opened at $45.30 on Wednesday. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $49.25. The company’s 50 day simple moving average is $43.85 and its 200 day simple moving average is $34.11. The stock has a market capitalization of $2.18 billion, a PE ratio of -2.17 and a beta of 4.47.

Insider Buying and Selling at Maze Therapeutics

In related news, CMO Harold Bernstein sold 45,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 200,000 shares of company stock valued at $8,254,792 over the last three months.

Institutional Trading of Maze Therapeutics

Hedge funds have recently made changes to their positions in the company. Ensign Peak Advisors Inc purchased a new stake in Maze Therapeutics during the 2nd quarter worth $227,000. Frazier Life Sciences Management L.P. grew its stake in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Washington University purchased a new stake in shares of Maze Therapeutics during the third quarter worth about $5,463,000. Virtus Investment Advisers LLC acquired a new position in shares of Maze Therapeutics in the second quarter worth about $85,000. Finally, CW Advisors LLC purchased a new position in Maze Therapeutics in the second quarter valued at about $371,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.